Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cytomegalovirus glycoprotein vaccine - GlaxoSmithKline

Drug Profile

Cytomegalovirus glycoprotein vaccine - GlaxoSmithKline

Alternative Names: GSK 1492903A; GSK Biologicals' recombinant CMV gB vaccine

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Cytomegalovirus vaccines; Glycopeptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cytomegalovirus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cytomegalovirus infections(Prevention) in Belgium (IM, Injection)
  • 27 Jan 2012 GlaxoSmithKline re-initiates enrolment in a phase I trial in Healthy volunteers in Belgium (NCT01357915)
  • 22 Sep 2011 GlaxoSmithKline completes enrolment in its phase I trial in Healthy volunteers in Belgium (NCT01357915)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top